Image source: Getty Images.
It’s been a good year for clinical-stage biotech Agenus Inc. (NASDAQ: AGEN): Its shares are up over 20% in 2016. Meanwhile, shares of peer Bellicum Pharmaceuticals (NASDAQ: BLCM) have sunk more than 20%. Which of these two biotech stocks presents the better choice for investors now?